Navigation Links
First-of-its-kind study shows benefits of electrical stimulation therapy for people paralyzed by spinal cord injury
Date:2/17/2011

study is that the research team could not get all participants to take part in a six-month follow-up assessment. However, six individuals who received FES therapy were assessed six months after the study. All had better hand function after six months than on the day they were discharged from the study.

Another study, now underway, will determine whether stimulation therapy can improve grasping ability in people with chronic (long-term) incomplete spinal cord injuries.

Administering stimulation therapy is easy and cost-effective, says Dr. Popovic, who stresses that it should augment, and not replace, existing occupational therapy.


'/>"/>

Contact: Carolyn Lovas
lovas.carolyn@torontorehab.on.ca
416-320-0147
Toronto Rehabilitation Institute
Source:Eurekalert  

Page: 1 2 3

Related biology news :

1. First-of-its-kind map details the height of the globes forests
2. American Sociological Association launches first-of-its-kind teaching tool
3. Designing new molecular tools to study the life and death of a cancer cell
4. Scripps Research study sheds light on RNA on/off switches
5. Study finds massive flux of gas, in addition to liquid oil, at BP well blowout in Gulf
6. Pulmonary fibrosis inhibited by pentraxin-2/SAP in research study
7. NSF funds study of landscape restoration effects on Pennsylvania stream
8. VTT to study one of worlds oldest beers
9. Brandeis study shows economic impact of dengue virus in Americas
10. Field study of smoggy inversions to end
11. Road may disrupt migration, ruin Serengeti, study finds
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
First-of-its-kind study shows benefits of electrical stimulation therapy for people paralyzed by spinal cord injury
(Date:5/11/2015)... N.Y. , May 11, 2015 Curemark ... announced the start of a new Phase III double ... of its novel formulation, CM-AT, on all children ages ... of its FDA Phase III double blinded clinical trial ... had low levels of the digestive enzyme chymotrypsin. This ...
(Date:5/6/2015)... 2015 LifeBEAM, a developer of bio-sensing technology, ... today that they will expand their partnership in bio-sensing ... cycling helmet and the first joint project between the ... in order to give cyclists more style choices and ... and Lazer announced their plan to release a new ...
(Date:4/27/2015)... , Apr. 27, 2015 Profile Solutions, Inc. ... and security systems is pleased to announce that Dr ... a consultant and member of its scientific advisory board. ... known as a thought leader in technology-enhanced learning models. ... Group, and has published studies and books focused on ...
Breaking Biology News(10 mins):Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2LifeBEAM and Lazer Announce Expanded Partnership in Bio-Sensing Sports Gear 2LifeBEAM and Lazer Announce Expanded Partnership in Bio-Sensing Sports Gear 3Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 2Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 3Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 4
... Testing people for heart disease might be just a finger ... by a team of researchers from Harvard and Northeastern universities ... FASEB Journal ( http://www.fasebj.org ), they describe how ... needed to build vascular tissue, called endothelial progenitor cells, using ...
... Boston, MA June 1, 2009 REGiMMUNE ... in combination with a low-dose of Sirolimus, demonstrated enhanced ... transplantation and acute Graft-versus-Host disease (GvHD). This data ... Tolerance Induction by a Liposomal Formulation of KRN7000 (RGI-2001) ...
... species are likely to respond to climate change. Most ... and the interactions between species, in the interest of ... BioScience , by Eric Post of Pennsylvania State University ... avoided. Their approach, which relies on multi-stage analyses of ...
Cached Biology News:New device detects heart disease using less than one drop of blood 2REGiMMUNE presents enhanced efficacy data in preclinical transplantation models 2
(Date:5/29/2015)... Texas , May 29, 2015  Caris ... focused on fulfilling the promise of precision medicine, ... studies that demonstrate the clinical utility of Caris ... tumor profiling service, in helping to identify targeted ... tumors. In each of the studies, results of ...
(Date:5/29/2015)... 29, 2015 Seoul Semiconductor (CEO: ... LED technology, on May 28th announced that it ... by strengthening its high efficient and high reliable ... Since 2011 Seoul Semiconductor has developed efficient and ... and has supplied LEDs for headlamps to global ...
(Date:5/28/2015)... May 28, 2015  Quest Diagnostics Incorporated (NYSE: ... services, announced that it is scheduled to speak at ... Steve Rusckowski , the company,s President and CEO, ... strategy.  The presentation is scheduled for Tuesday, June 2, ... presentation will be webcast live during the conference and ...
(Date:5/28/2015)... -- Research and Markets( http://www.researchandmarkets.com/research/6cg3zw/cell_therapy ) has announced ... "Cell Therapy - Technologies, Markets and Companies" ... and evaluates cell therapy technologies and methods, which ... in the practice of medicine. Hematopoietic stem cell ... transplants. Role of cells in drug discovery is ...
Breaking Biology Technology:Multi-Platform Tumor Profiling from Caris Life Sciences Identifies Targeted Treatment Options for Patients with Rare and/or Aggressive Tumors 2Multi-Platform Tumor Profiling from Caris Life Sciences Identifies Targeted Treatment Options for Patients with Rare and/or Aggressive Tumors 3Multi-Platform Tumor Profiling from Caris Life Sciences Identifies Targeted Treatment Options for Patients with Rare and/or Aggressive Tumors 4Multi-Platform Tumor Profiling from Caris Life Sciences Identifies Targeted Treatment Options for Patients with Rare and/or Aggressive Tumors 5Multi-Platform Tumor Profiling from Caris Life Sciences Identifies Targeted Treatment Options for Patients with Rare and/or Aggressive Tumors 6Seoul Semiconductor Increases the Global Automotive LED Market Share with its High Efficient and Reliable LEDs for Automotive Lightings 2Quest Diagnostics to Speak at the Jefferies 2015 Global Healthcare Conference 2Global Cell Therapy Market 2015-2020 - Technologies, Markets and Companies 2
... Genoptix, Inc.,(Nasdaq: GXDX ), a specialized ... the BIOCOM Investor Conference 2008,scheduled to take place ... on October,26-28, 2008., Dr. Tina Nova, President ... on Monday, October 27, beginning at approximately 9:30 ...
... ... - Results Presented at the 20th EORTC-NCI-AACR Symposium on Molecular ... Targets and Cancer Therapeutics -, GENEVA and SAN FRANCISCO, ... new data from an,ongoing Phase 1-2 clinical trial demonstrating that the Company,s novel,androgen ...
... Presented at 20th EORTC-NCI-AACR Symposium -, ... 22 /PRNewswire-FirstCall/,-- Poniard Pharmaceuticals, Inc. (Nasdaq: ... today announced positive incremental data from,its randomized, ... in patients,with metastatic colorectal cancer (CRC). The ...
Cached Biology Technology:Genoptix Announces Participation at the BIOCOM Investor Conference 2008 2Medivation Announces Presentation of 24-Week Clinical Data of MDV3100 in Castration-Resistant Prostate Cancer Patients 2Medivation Announces Presentation of 24-Week Clinical Data of MDV3100 in Castration-Resistant Prostate Cancer Patients 3Medivation Announces Presentation of 24-Week Clinical Data of MDV3100 in Castration-Resistant Prostate Cancer Patients 4Poniard Announces Positive Incremental Efficacy and Safety Data from Phase 2 Picoplatin Trial in Patients With Metastatic Colorectal Cancer 2Poniard Announces Positive Incremental Efficacy and Safety Data from Phase 2 Picoplatin Trial in Patients With Metastatic Colorectal Cancer 3Poniard Announces Positive Incremental Efficacy and Safety Data from Phase 2 Picoplatin Trial in Patients With Metastatic Colorectal Cancer 4Poniard Announces Positive Incremental Efficacy and Safety Data from Phase 2 Picoplatin Trial in Patients With Metastatic Colorectal Cancer 5
Buckets for tube holder inserts...
45° Fixed Angle Rotor for use in the IEC Centra CL2, Centra CL3/CL3R, HN-SII, and the Centra-MP4/MP4R....
... 10-2 is a microprocessor controlled, high ... coupled with exceptionally smooth operation make ... applications involving fluorescence microscopy, ratio imaging, ... requiring rapid and accurate aperture positioning. ...
... Fluoroskan Ascent FL is ... and luminometric measurement technologies ... list of advanced features ... Luminoskan Ascent. Fluoroskan Ascent ...
Biology Products: